Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA5284854
Max Phase: Preclinical
Molecular Formula: C22H21NO3
Molecular Weight: 347.41
Associated Items:
ID: ALA5284854
Max Phase: Preclinical
Molecular Formula: C22H21NO3
Molecular Weight: 347.41
Associated Items:
Canonical SMILES: O=C1/C(=C/c2ccc(N3CCCCC3)cc2)Cc2cc3c(cc21)OCO3
Standard InChI: InChI=1S/C22H21NO3/c24-22-17(11-16-12-20-21(13-19(16)22)26-14-25-20)10-15-4-6-18(7-5-15)23-8-2-1-3-9-23/h4-7,10,12-13H,1-3,8-9,11,14H2/b17-10+
Standard InChI Key: MFTXMRSWEYWASY-LICLKQGHSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 347.41 | Molecular Weight (Monoisotopic): 347.1521 | AlogP: 4.23 | #Rotatable Bonds: 2 |
Polar Surface Area: 38.77 | Molecular Species: NEUTRAL | HBA: 4 | HBD: 0 |
#RO5 Violations: 0 | HBA (Lipinski): 4 | HBD (Lipinski): 0 | #RO5 Violations (Lipinski): 0 |
CX Acidic pKa: | CX Basic pKa: 5.24 | CX LogP: 4.47 | CX LogD: 4.47 |
Aromatic Rings: 2 | Heavy Atoms: 26 | QED Weighted: 0.76 | Np Likeness Score: -0.31 |
1. Altıntop MD, Özdemir A, Temel HE, Demir Cevizlidere B, Sever B, Kaplancıklı ZA, Akalın Çiftçi G.. (2022) Design, synthesis and biological evaluation of a new series of arylidene indanones as small molecules for targeted therapy of non-small cell lung carcinoma and prostate cancer., 244 [PMID:36270087] [10.1016/j.ejmech.2022.114851] |
Source(1):